Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis

• Published in: Diabetes & metabolic syndrome clinical research & reviews Vol. 15; no. 5; p. 102210
• Main Authors: Alsagaff, Mochamad Yusuf, Mulia, Eka Prasetya Budi, Maghfirah, Irma, Luke, Kevin, Nugraha, David, Rachmi, Dita Aulia, Septianda, Imanita, A'yun, Maya Qurota
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.09.2021; Diabetes India. Published by Elsevier Ltd
• Subjects: Calcium channel blocker; COVID-19; Hypertension; Mortality; Review; Severity; COVID-19; Hypertension; Severity; Calcium channel blocker; Mortality
• ISSN: 1871-4021; 1878-0334
• DOI: 10.1016/j.dsx.2021.102210

This meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes. PubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality. A total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI: 0.98–1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI: 0.52–0.91], p = 0.009). CCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients. •CCB usage was not associated with the outcome of COVID-19 in the general population.•In hypertensive patients, CCB was associated with decreased mortality.•The certainty of the evidence for mortality reduction was very low.